- Pharmacology
- Allergy, Immunology, and ENT
- Cardiology
- Emergency Medicine
- Endocrinology
- Adolescent Medicine
- Gastroenterology
- Infectious Diseases
- Neurology
- OB/GYN
- Practice Improvement
- Gynecology
- Respiratory
- Dermatology
- Mental, Behavioral and Development Health
- Oncology
- Rheumatology
- Sexual Health
- Pain
FDA approves oral treatment for spinal muscular atrophy
The US Food and Drug Administration (FDA) approved Evrysdi (risdiplam) to treat spinal muscular atrophy. It is the third drug approved to treat the condition.
The US Food and Drug Administration (FDA) has approved Evrysdi (risdiplam) from Genentech, Inc. to treat spinal muscular atrophy (SMA) in children aged 2 months and older.1 It is the third drug to treat SMA that has been approved by the FDA and the first oral drug. The approval was given orphan drug designation as well as a Rare Pediatric Disease Priority Review Voucher. Spinal muscular atrophy is a rare hereditary disease that causes muscle wasting and weakness. It is often fatal.
The efficacy of risdiplam was illustrated in 2 clinical studies. In an infantile-onset SMA study, efficacy was defined as the ability for a child to sit without support for at least 5 seconds and survival that didn’t require permanent ventilation. Following 12 months of treatment, 41% of the patients were able to sit without support for more than 5 seconds, which was a noticeable contrast with the natural progression of SMA. Following 23 months or more of treatment with risdiplam, 81% of the patients were alive without a need for permanent ventilation, which was another notable improvement over typical disease progression. The other later-onset SMA study looked at the score of a motor function test after a year of treatment. Participants who were given risdiplam had a mean increase in their score of 1.36 and the inactive treatment patients saw a mean decrease in the score of 0.19.
Side effects included diarrhea, rash, ulcers of the mouth area, joint pain, urinary tract infections, and fever. The infantile-onset study also reported vomiting, constipation, pneumonia, and upper respiratory tract infection. Risdiplam shouldn’t be taken with drugs that are multidrug and toxin extrusion substrates.
Reference
1. US Food and Drug Administration. FDA approves oral treatment for spinal muscular atrophy. US Food and Drug Administration. Published August 7, 2020. Accessed August 11, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.
